Sign In
Buy ALPN
$64.97
+0 (+0%)
At Close: Aug 19, 2024
Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Lags Revenue Estimates
07:03pm, Thursday, 23'rd Mar 2023
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -51.85% and 73.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseas
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc.
Alpine Immune Sciences to Report Fourth Quarter and Full Year 2022 Financial Results
04:30pm, Wednesday, 15'th Mar 2023
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseas
Alpine Immune Sciences, Inc. (ALPN) Q3 2022 Earnings Call Transcript
07:09pm, Monday, 14'th Nov 2022
Alpine Immune Sciences, Inc. (NASDAQ:ALPN ) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET Company Participants Temre Johnson - SD, IR Mitchell Gold - Executive Chairman, CEO Stanford Pe
Alpine Immune Sciences, Inc. (ALPN) Reports Q3 Loss, Misses Revenue Estimates
06:48pm, Monday, 14'th Nov 2022
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -320% and 59.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for t
Alpine Immune Sciences to Report Third Quarter 2022 Financial Results
04:30pm, Monday, 07'th Nov 2022
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseas
Strength Seen in Alpine Immune Sciences, Inc. (ALPN): Can Its 7.5% Jump Turn into More Strength?
08:46am, Friday, 04'th Nov 2022 Zacks Investment Research
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in t
Strength Seen in Alpine Immune Sciences, Inc. (ALPN): Can Its 7.5% Jump Turn into More Strength?
06:01am, Friday, 04'th Nov 2022
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in t
After Plunging 23.2% in 4 Weeks, Here's Why the Trend Might Reverse for Alpine Immune Sciences, Inc. (ALPN)
01:35pm, Friday, 28'th Oct 2022 Zacks Investment Research
Alpine Immune Sciences, Inc. (ALPN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street a
After Plunging 23.2% in 4 Weeks, Here's Why the Trend Might Reverse for Alpine Immune Sciences, Inc. (ALPN)
11:18am, Friday, 28'th Oct 2022
Alpine Immune Sciences, Inc. (ALPN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street a
Alpine Immune Sciences: ALPN-202 May Be Dead, But The Company Isn't
10:33am, Thursday, 27'th Oct 2022
The recent termination of ALPN-202 trials due to another patient's death caused the share price to plummet. While this was anticipated, I believe that the market has overreacted due to several reasons
Alpine: Ramifications Of The Davoceticept Termination
05:51am, Thursday, 27'th Oct 2022
The second patient death prompted Alpine to terminate any future development of davoceticept. It's prudent that Alpine stopped unfruitful developments early on to focus on lower-hanging fruits.
What Happened This Week: Poor Earnings Reports And Buybacks
08:23pm, Friday, 21'st Oct 2022 Investing.com
Esperion Therapeutics (ESPR) Moves 6.5% Higher: Will This Strength Last?
12:22pm, Wednesday, 12'th Oct 2022 Zacks Investment Research
Esperion Therapeutics (ESPR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric
